Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arsenal Biosciences and Genentech have entered a multi-year collaboration for identifying features of T-Cell therapies for oncology.
ArsenalBio, Genentech team up to identify features of T-Cell therapies for oncology. Credit: National Cancer Institute on Unsplash.
Subscribe to our email newsletter
As part of the collaboration deal, the companies will use ArsenalBio’s T cells screening and engineering technology for identifying the critical success circuits in T cell-based therapies.
Genentech, a member of Roche Group, and Arsenal Biosciences will also use automation, large-scale genome engineering, high-content profiling and advanced machine learning and artificial intelligence (AI) algorithms for advancing the design, development, and testing of next-generation cell treatments for cancer.
Under the deal terms, both the companies will deploy synergistic capabilities for studying effective T cell-based modifications and gain new understandings of their impacts through preclinical analysis.
The two firms will leverage these learnings in developing future therapeutic candidates.
ArsenalBio CEO Ken Drazan said: “We are proud to be working with Genentech, a pioneer in immunology, cancer, and now the application of machine learning research, to better understand how to leverage the immune system for the treatment of cancer.
“This collaboration is a testament to the strength of our platforms and their utility in identifying the attributes of T cells that offer the most promise in addressing unmet medical needs across cancer.”
As per terms of the collaboration agreement, Arsenal will receive an upfront payment of $70m, as well as research, development, and commercial milestones.
ArsenalBio stated that its advanced engineering platform deploys an array of technologies that include CRISPR-based gene editing, synthetic biology, and computational biology.
The platform helps in creating new synthetic biological programmes that will improve T cell functions and overcome the complex immunological defence systems in and around the solid tumours.
